Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469725 | 0.86 | HRH2 (0.46) | HRH2HRH3HRH4PSMB5NUDT1 | |
| SCHEMBL6470547 | 0.77 | ADK (0.37) | HRH2HRH3HRH4PSMB5NUDT1 | |
| SCHEMBL27941496 | 0.77 | HRH3 (0.50) | HRH2HRH3HRH4GHSR | |
| SCHEMBL6469727 | 0.76 | PSMB5 (0.38) | HRH2HRH3HRH4PSMB5NUDT1 | |
| SCHEMBL5539981 | 0.72 | PSMB5 (0.42) | HRH3HRH4PSMB5NUDT1ADK | |
| SCHEMBL6473618 | 0.70 | HRH2 (0.51) | HRH2HRH3HRH4NUDT1GHSR | |
| SCHEMBL5705351 | 0.68 | NOS1 (0.33) | NUDT1NOS1 | |
| SCHEMBL12268234 | 0.67 | HRH2 (0.36) | HRH2HRH3 | |
| SCHEMBL31475661 | 0.67 | HRH2 (0.43) | HRH2HRH3NUDT1 | |
| SCHEMBL2745568 | 0.67 | HRH3 (0.47) | HRH2HRH3HRH4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | HRH2 43/4885HRH3 25/4885HRH4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.